| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.86 [0.72, 1.03] | | < 1 | | 66% | 4 studies (4/-) | 95.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.66 [0.55, 0.80] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.68 [0.57, 0.82] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.82 [0.67, 1.00] | | < 1 | | 71% | 5 studies (5/-) | 97.2 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.35 [0.99, 1.84] | | > 1 | | 72% | 5 studies (5/-) | 97.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.51 [0.27, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.02 [0.76, 1.37] | | < 1 | | 0% | 1 study (1/-) | 44.6 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 2.19 [1.17, 4.11] | | < 1 | | 0% | 1 study (1/-) | 0.7 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.43 [0.97, 2.10] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 2.14 [1.32, 3.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.93 [1.22, 3.04] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.90 [1.55, 2.32] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 1.83 [1.47, 2.28] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.78 [0.38, 1.62] | | < 1 | | 91% | 4 studies (4/-) | 74.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.94 [0.62, 1.42] | | < 1 | | 83% | 4 studies (4/-) | 61.5 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.25 [0.61, 2.53] | | < 1 | | 0% | 3 studies (3/-) | 27.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 2.62 [1.73, 3.95] | | < 1 | | 61% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 3.56 [2.57, 4.94] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 6.74 [0.82, 55.04] | | < 1 | | 0% | 2 studies (2/-) | 3.8 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.17 [0.06, 0.46] | | < 1 | | 69% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.59 [0.21, 1.68] | | < 1 | | 39% | 4 studies (4/-) | 83.8 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 11.58 [1.50, 89.46] | | < 1 | | 0% | 2 studies (2/-) | 1.0 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.69 [0.11, 4.24] | | < 1 | | 0% | 4 studies (4/-) | 65.6 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.84 [0.40, 1.79] | | < 1 | | 0% | 4 studies (4/-) | 67.2 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 3.83 [1.72, 8.51] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 1.46 [0.64, 3.34] | | < 1 | | 29% | 4 studies (4/-) | 18.3 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 1.38 [0.60, 3.15] | | < 1 | | 0% | 1 study (1/-) | 22.3 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 13.52 [0.76, 239.13] | | < 1 | | 0% | 1 study (1/-) | 3.9 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 2.72 [0.39, 19.13] | | < 1 | | 0% | 3 studies (3/-) | 15.9 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.46 [0.47, 12.75] | | < 1 | | 0% | 1 study (1/-) | 14.3 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 7.55 [2.24, 25.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 4.93 [0.57, 42.41] | | < 1 | | 0% | 1 study (1/-) | 7.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.59 [0.20, 1.77] | | < 1 | | 37% | 4 studies (4/-) | 82.7 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.74] | | < 1 | | 84% | 4 studies (4/-) | 98.5 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 7.74 [0.96, 62.17] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 3.67 [0.73, 18.44] | | < 1 | | 0% | 4 studies (4/-) | 5.8 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 5.99 [1.42, 25.24] | | < 1 | | 0% | 4 studies (4/-) | 0.7 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.21 [0.01, 8.21] | | < 1 | | 84% | 2 studies (2/-) | 79.4 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.26 [0.06, 1.14] | | < 1 | | 56% | 4 studies (4/-) | 96.3 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Alopecia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.36 [0.04, 3.34] | | < 1 | | 91% | 2 studies (2/-) | 81.4 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia AE (grade 3-4) | 2.01 [0.36, 11.05] | | < 1 | | 0% | 1 study (1/-) | 21.3 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.70 [0.29, 1.72] | | < 1 | | 7% | 2 studies (2/-) | 77.9 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 0.58 [0.14, 2.44] | | < 1 | | 0% | 2 studies (2/-) | 77.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation AE (grade 3-4) | 1.29 [0.28, 5.92] | | < 1 | | 0% | 2 studies (2/-) | 37.1 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 0.66 [0.05, 8.56] | | < 1 | | 0% | 2 studies (2/-) | 62.5 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 1.78 [0.55, 5.75] | | < 1 | | 0% | 2 studies (2/-) | 16.7 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 3.61 [0.84, 15.63] | | < 1 | | 44% | 2 studies (2/-) | 4.3 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea AE (grade 3-4) | 0.97 [0.46, 2.06] | | < 1 | | 0% | 2 studies (2/-) | 52.8 % | low | not evaluable | high | non important | - |
| Fatigue AE (grade 3-4) | 1.38 [0.65, 2.91] | | < 1 | | 0% | 2 studies (2/-) | 20.1 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.00 [0.06, 16.01] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 2.52 [0.48, 13.09] | | < 1 | | 0% | 1 study (1/-) | 13.7 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 2.28 [0.69, 7.50] | | < 1 | | 0% | 1 study (1/-) | 8.7 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.90 [0.21, 3.82] | | < 1 | | 15% | 2 studies (2/-) | 55.4 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.01 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 1.36 [0.72, 2.56] | | < 1 | | 0% | 1 study (1/-) | 17.2 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 2.21 [0.83, 5.91] | | < 1 | | 0% | 1 study (1/-) | 5.6 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.59 [0.08, 4.61] | | < 1 | | 0% | 2 studies (2/-) | 69.1 % | low | not evaluable | high | non important | - |
| Pyrexia AE (grade 3-4) | 3.05 [0.28, 33.02] | | < 1 | | 0% | 2 studies (2/-) | 18.1 % | low | not evaluable | high | non important | - |
| Rash AE (grade 3-4) | 3.86 [0.24, 62.86] | | < 1 | | 49% | 2 studies (2/-) | 17.4 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.72 [0.03, 20.37] | | < 1 | | 79% | 2 studies (2/-) | 57.5 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased AE (grade 3-4) | 2.86 [0.30, 27.64] | | < 1 | | 0% | 1 study (1/-) | 18.3 % | NA | not evaluable | | non important | - |
